Medical progress should also provide more effective and affordable therapies for the diseases or disorders that come with age. Ideally, preventative intervention can avoid costly disease in the first place, e.g., lifestyle-related cardiovascular complications. However, this approach seems less effective with cancer, another leading cause of death that carried a cumulative healthcare burden in excess of USD 1.2 trillion in 2010, according to the World Health Organization. Unlike other cancer risk factors such as smoking and an unhealthy lifestyle, aging cannot be avoided. Next-generation technologies, such as antibody-drug conjugates and personalized cancer vaccines, are making great strides in clinical testing. Considering the industry’s full oncology pipeline, it will be paramount that healthcare systems exploit the full savings potential from patent expiries through the development of generics as well as biosimilar products of biologic drugs, creating financial headway for innovation.